⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737186 | 0.79 | — | — | |
| SCHEMBL734711 | 0.77 | — | — | |
| SCHEMBL1102254 | 0.73 | — | — | |
| SCHEMBL840154 | 0.69 | — | — | |
| SCHEMBL840809 | 0.65 | — | — | |
| SCHEMBL1101993 | 0.64 | — | — | |
| SCHEMBL318964 | 0.62 | — | — | |
| Iodide SCHEMBL25395085 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL1042634 | 0.60 | — | — | |
| Water SCHEMBL28563407 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | claimed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | claimed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| CN-108026133-B | Novel aminoglycoside antibiotics effective against multidrug resistant bacteria | 公益财团法人微生物化学研究会 | 2021-05-07 | — | — | CN | disclosed |
| WO-2020085493-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-04-30 | — | — | WO | disclosed |
| WO-2020085504-A1 | METHOD FOR PRODUCING CHLOROAZOLE CARBOXYLATE DERIVATIVE USING SANDMEYER REACTION WITH LIGHT IRRADIATION | 大鵬薬品工業株式会社 | 2020-04-30 | — | — | WO | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |